246 related articles for article (PubMed ID: 31516032)
21. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Sekeres MA; Schuster M; Joris M; Krauter J; Maertens J; Breems D; Gyan E; Kovacsovics T; Verma A; Vyas P; Wang ES; Ching K; O'Brien T; Gallo Stampino C; Ma WW; Kudla A; Chan G; Zeidan AM
Ann Hematol; 2022 Aug; 101(8):1689-1701. PubMed ID: 35488900
[TBL] [Abstract][Full Text] [Related]
22. Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
Cortes JE; Candoni A; Clark RE; Leber B; Montesinos P; Vyas P; Zeidan AM; Heuser M
Leuk Lymphoma; 2020 Dec; 61(14):3287-3305. PubMed ID: 32967493
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
Ruiz-Garcia A; Shaik N; Lin S; Jamieson C; Heuser M; Chan G
J Clin Pharmacol; 2021 Mar; 61(3):349-359. PubMed ID: 32974950
[TBL] [Abstract][Full Text] [Related]
24. Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
Tavares M; Chacim S; Mariz JM
Ann Hematol; 2021 Mar; 100(3):837-839. PubMed ID: 33001280
[No Abstract] [Full Text] [Related]
25. Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
Zucenka A; Maneikis K; Pugaciute B; Ringeleviciute U; Dapkeviciute A; Davainis L; Daukelaite G; Burzdikaite P; Staras V; Griskevicius L
Ann Hematol; 2021 May; 100(5):1195-1202. PubMed ID: 33661333
[TBL] [Abstract][Full Text] [Related]
26. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
27. Update on glasdegib in acute myeloid leukemia - broadening horizons of Hedgehog pathway inhibitors.
Fersing C; Mathias F
Acta Pharm; 2022 Mar; 72(1):9-34. PubMed ID: 36651529
[TBL] [Abstract][Full Text] [Related]
28. Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
[TBL] [Abstract][Full Text] [Related]
29. Glasdegib in newly diagnosed acute myeloid leukemia.
Sarkaria SM; Heaney ML
Expert Rev Anticancer Ther; 2021 Jun; 21(6):573-581. PubMed ID: 33593233
[TBL] [Abstract][Full Text] [Related]
30. Is the overall survival for older adults with AML finally improving?
Lancet JE
Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
[TBL] [Abstract][Full Text] [Related]
31. Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient.
Fathi AT
Clin Cancer Res; 2019 Oct; 25(20):6015-6017. PubMed ID: 31324656
[TBL] [Abstract][Full Text] [Related]
32. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
[TBL] [Abstract][Full Text] [Related]
33. AML: New Drugs but New Challenges.
Burnett A; Stone R
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
[TBL] [Abstract][Full Text] [Related]
34. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
35. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
36. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
37. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Macdonald DA; Assouline SE; Brandwein J; Kamel-Reid S; Eisenhauer EA; Couban S; Caplan S; Foo A; Walsh W; Leber B
Leuk Lymphoma; 2013 Apr; 54(4):760-6. PubMed ID: 23061485
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
Serve H; Krug U; Wagner R; Sauerland MC; Heinecke A; Brunnberg U; Schaich M; Ottmann O; Duyster J; Wandt H; Fischer T; Giagounidis A; Neubauer A; Reichle A; Aulitzky W; Noppeney R; Blau I; Kunzmann V; Stuhlmann R; Krämer A; Kreuzer KA; Brandts C; Steffen B; Thiede C; Müller-Tidow C; Ehninger G; Berdel WE
J Clin Oncol; 2013 Sep; 31(25):3110-8. PubMed ID: 23897964
[TBL] [Abstract][Full Text] [Related]
39. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
Grishina O; Schmoor C; Döhner K; Hackanson B; Lubrich B; May AM; Cieslik C; Müller MJ; Lübbert M
BMC Cancer; 2015 May; 15():430. PubMed ID: 26008690
[TBL] [Abstract][Full Text] [Related]
40. Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia.
Thompson DL; Moore DC
J Adv Pract Oncol; 2020 Mar; 11(2):196-200. PubMed ID: 33532119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
